Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Resource Library

CTEPH Resources

Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Resources on PHA Online University

Chronic thromboembolic pulmonary hypertension (CTEPH) is a form of pulmonary hypertension caused by pulmonary embolism (PE) that remains unresolved after at least three months of anticoagulation. CTEPH occurs in a minority of PE patients, and some studies suggest that most CTEPH patients present with no known history of PE.

The symptoms experienced by CTEPH patients are similar to those of other types of pulmonary hypertension (PH). CTEPH is unique among the five groups of pulmonary hypertension (PH) in that it is potentially curable with pulmonary thromboendarterectomy (PTE) surgery.* However, not all patients are good candidates for surgery. Every patient diagnosed with CTEPH should be evaluated by an expert CTEPH team, including CTEPH physicians and a PTE surgeon, to determine their eligibility for the procedure.


*Sometimes referred to as PEA 


Learn more about CTEPH on PHA Online University:


  • Chronic Thromboembolic Disease: When Do We Operate?: Natalie Kitterman, RN; Richard Channick, MD and William Auger, MD
    • 2007 PH Resource Network Symposium
      • This abstract discusses when to operate and provide a nursing perspective on a patient diagnosed with CTEPH while being referred for thromboendarterectomy.
  • Impact of Riociguat on Health-Related Quality of Life in Patients with CTEPH: David Badesch, MD
    • 2014 International PHA Conference and Scientific Sessions
      • In the Phase III PATENT-1 study, riociguat, a novel soluble guanylate cyclase stimulator, was well tolerated and significantly improved 6-minute walking distance as well as consistently improving a range of clinically relevant secondary endpoints in patients with pulmonary arterial hypertension (PAH). The objective of this analysis was to evaluate the impact of riociguat on health-related quality of life (HRQoL) during PATENT-1.
  • First Pulmonary Endarterectomy in Latvia
    • 2014 Conference Abstracts
      • Pulmonary endarterectomy (PEA) is the treatment of choice for patients with chronic thromboembolic pulmonary hypertension (CTEPH) and it is used to reduce pulmonary vascular resistance with significant symptomatic and prognostic benefit.

Advances in Pulmonary Hypertension

  • Chronic Thromboembolic Pulmonary Hypertension, Winter 2014 (Vol 12, No 4)
    • An entire journal of PHA's medical journal Advances in Pulmonary Hypertension has been dedicated to CTEPH. Overview: "We now know that a VQ scan is the test of choice to 'rule out' and diagnose CTEPH. A good portion of patients do not have a history of prior pulmonary embolism when they present with CTEPH. PTE should be considered for every patient who is diagnosed with CTEPH because it is the only form of PH that is potentially curable with a well-planned and appropriate surgical intervention."


  • WHO Group 4 PH (CTEPH) - William R. Auger, MD
    • Learn to describe the clinical definition of chronic thromboembolic pulmonary hypertension (CTEPH); explain the rationale for screening all pulmonary hypertension patients for CTEPH; describe risk factors for developing CTEPH; recognize the clinical presentation and diagnostic algorithm for CTEPH; and describe treatment options for CTEPH patients.
  • WHO Group 4 PH (CTEPH) Treatment: Surgical v. Medical - Richard N. Channick, MD
    • Learn to describe the role of CT angiography in assessing surgical accessibility; discern operable versus inoperable chronic thromboembolic disease; interpret the surgical classification for CTEPH; explain the benefits of a pulmonary thromboendarterectomy; and discuss the therapeutic options for those patients with inoperable or recurrent CTEPH, including PAH-targeted medical therapy and/or balloon pulmonary angioplasty.
  • Chronic Thromboembolic Pulmonary Hypertension (CTEPH):Finding, Treating, and Future Directions -Josanna Rodriguez-Lopez, MD
    • Learn to recognize patient populations at risk for developing CTEPH; describe screening and diagnostic recommendations in patients with unexplained shortness of breath; and summarize current treatment options, as well as the benefits and risks of each, for patients with CTEPH.

Diagnosis & Treatments

  • WHO Group 4: CTEPH
    • Read about a general overview of CTEPH and how it distinguishes itself from pulmonary arterial hypertension (PAH)

Partner Presentations

  • CTEPH - National Proceedings: CTEPH 2016, conference held in La Jolla, California
    • National Proceedings: CTEPH 2016 was planned to provide an overview of the most recent information on the evaluation and management of patients with chronic thromboembolic pulmonary hypertension (CTEPH). The role of PH directed medical therapy and balloon pulmonary angioplasty in the treatment of CTEPH patients were the highlighted topics of this conference. An update on the epidemiology of CTEPH in the United States, the status of the US CTEPH Registry, and a review of the pathophysiology of chronic thromboembolic pulmonary vascular disease was additionally presented. The conference format was comprised of didactic presentations, debates, and panel discussions involving national and international experts in the field, with an emphasis on interactive audience participation. An added feature to the 2016 symposium was the opportunity for participants to submit and present scientific abstracts and unique clinical cases related to CTEPH and chronic thromboembolic pulmonary vascular disease. 


  Sign in to add a review